相关产品推荐更多 >

CD140b Antibody, anti-human, APC-Vio® 770, REAfinity™, 100 tests in 200 µL
询价
CD203c Antibody, anti-human, PE-Vio® 770, 30 tests in 300 µL
询价
CD88 (C5AR) Antibody, anti-human, APC, 100 tests in 1 mL
询价
c-Cbl pY774 Antibody, anti-human, PE, REAfinity™, 100 tests in 1 mL
询价
CD338 (ABCG2) Antibody, anti-human, APC, 30 tests in 300 µL
询价
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原:
Glucagon
- 形态:
Reagents are supplied in buffer containing stabilizer and 0.05% sodium azide.
- 保存条件:
避光,4-8℃
- 克隆性:
REAL1173
- 标记物:
PE
- 适应物种:
human
- 保质期:
24个月
- 供应商:
Miltenyi biotec
- 宿主:
cell line
- 应用范围:
MICS (MACSima Imaging Cyclic Staining), Immunofluorescence, Immunohistochemistry
- 抗体英文名:
Glucagon Antibody, anti-human, REAdye_lease™
- 抗体名:
Glucagon Antibody, anti-human, REAdye_lease™
- 规格:
200 µL
Detection of Glucagon+ cellsClone REAL1173 is an antibody fragment derived from the full Glucagon antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity. | Clone REAL1173 recognizes human Glucagon, also known as GCG, which is predominantly secreted from the alpha cells of the pancreas. Glucogon is cleaved into 8 chains and plays a key role in glucose metabolism and homeostasis. Glucagon is stimulated by hypoglycemia and inhibited by hyperglycemia, insulin, and somatostatin. It raises plasma glucose levels in response to insulin-induced hypoglycemia and therfore is important in initiating and maintaining hyperglycemic conditions in diabetes. Used to treat severe hypoglycemia in insulin-dependent diabetics. | For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675). |
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验该产品被引用文献
Kulina, G. R. et al. (2016) THE ROLE OF GLUCAGON IN THE PATHOPHYSIOLOGY AND MANAGEMENT OF DIABETES. Endocr Pract. 22 (5): 612–621. | Chabenne, J. R. et al. (2020) Structural Refinement of Glucagon for Therapeutic Use. J. Med. Chem. 663 (7): 3447–3460. | Janah, L. et al. (2019) Glucagon Receptor Signaling and Glucagon Resistance. Int J Mol Sci 20 (13): 3314.
技术资料暂无技术资料 索取技术资料
文献支持
Glucagon Antibody, anti-human, PE, REAdye_lease™, 200 µL
询价





